Abstract:Background: In breast cancer, over one third of all patients harbor a somatic mutation in the PIK3CA gene, encoding the p110α catalytic subunit of the phosphatidylinositol 3-kinase (PI3K) in their tumor cells. Circulating tumor cells (CTCs) are cells shed from the primary tumor into the blood stream. Recently, the long-term stable breast cancer CTC-ITB-01 cell line with tumorigenic and metastatic capacity was established from liquid biopsy derived cells. The oncogenic hotspot PIK3CA mutation H1047R (kinase domain) was detected in the primary tumor, CTCs and metastasis of the same patient. Other PIK3CA mutations located within the C2 domain (E418K and E453K) were detected in the CTCs and the vaginal metastasis but not in the primary tumor. The goal of our study was to functionally characterize the impact of the rare E418K and E453K mutations within the C2 domain that were not detected in the primary tumor. Methods: PIK3CA mutations E418K, E453K, H1047R were generated by site-directed mutagenesis and stably overexpressed in breast cancer cells by lentiviral transduction. Subsequent signaling pathway activation was examined by western blot analysis. The impact of PIK3CA mutations on biological processes was studied by live cell imaging using the Incucyte Zoom system. Structural modeling was conducted in Pymol. The membrane localization of the mutants was evaluated by separating the cytosolic and membrane fraction using ultracentrifugation. Drug susceptibility of CTC-ITB-01 cells was analyzed by live cell imaging. Results: Western blot analysis of human MDA-MB-231, MCF-7 and T47D breast cancer cells stably overexpressing either the PIK3CA wildtype (WT) or one of the E418K, E453K or H1047R mutants revealed a significant increase in AKT phosphorylation in both C2 mutants (E418K and E453K) and the kinase domain mutant H1047R. Functional analysis showed a significantly increased proliferation of MDA-MB-231 cells overexpressing the E453K and H1047R mutants. Migration was increased in all cells overexpressing WT and each of the mutants. Interestingly, invasion and chemotaxis were only enhanced in the MDA-MB-231 cells overexpressing the C2 domain mutants, i.e. E418K and E453K. In addition, membrane localization of the two C2 domain mutants was increased. Structural modeling of the E453K mutation suggests a disruption of the interaction between the negative regulatory domain of the p85α subunit and the p110α catalytic subunit as a potential mechanism leading to the observed activation of PI3K/AKT/mTOR signaling. Dual targeting of AKT/mTOR pathway by MK2206 and RAD001 leads to very strong synergistic effects (IC50 MK2206: 148 nM, IC50 RAD001: 15 nM) with respect to proliferation in the CTC-ITB-01 line through apoptosis induction. Conclusions: Our results demonstrate that PIK3CA C2 domain mutations activate PI3K downstream AKT signaling and can increase proliferation, migration and invasion after stable lentiviral transduction. Although both investigated mutations - E418K and E453K - are located within the C2 domain, a different molecular mechanism can be proposed. The PIK3CA mutated CTC-ITB-01 shows a high susceptibility against dual inhibition of AKT/mTOR. Further studies are required to fully elucidate the oncogenic potential of rare PIK3CA mutations.

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

Mutation And Functional Analysis Of Pik3ca And Pik3r1 In Endometrial Cancer

Data from High Frequency of <i>pik3r1</i> and <i>pik3r2</i> Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

Abstract B028: Epithelial-specific loss of PIK3R1 in a murine model result in endometrial hyperplasia

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer

PIK3CA mutations in endocrine-resistant breast cancer

Improved survival associated with somatic PIK3CA mutations in copy-number low endometrioid endometrial adenocarcinoma

[Significance of Phosphoinositide 3 Kinase/akt Pathway Alterations in Endometrial Carcinoma].

Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells

PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers

Correction: PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.

Phosphatidyl Inositol-3 Kinase (PIK3CA) E545K Mutation Confers Cisplatin Resistance and a Migratory Phenotype in Cervical Cancer Cells

PI3KCA Mutations in Uterine Cervix Carcinoma

Phosphatidylinositol 3-hydroxy Kinase and Endometrial Cancer

The Oncogene Phosphatidylinositol 3'-Kinase Catalytic Subunit Alpha Promotes Angiogenesis Via Vascular Endothelial Growth Factor in Ovarian Carcinoma.

Integrative Genomic Analysis of Phosphatidylinositol 3′-Kinase Family Identifies PIK3R3 As a Potential Therapeutic Target in Epithelial Ovarian Cancer

PIK3CA-mutations in breast cancer

Roles of Genetic Variants in the PI3K and RAS/RAF Pathways in Susceptibility to Endometrial Cancer and Clinical Outcomes

Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade

Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation